Company Novo Nordisk A/S Xetra

Company Novo Nordisk A/S Xetra

DK0060102614

Pharmaceuticals

Equities

DK0060102614

Pharmaceuticals

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Group companies

Sector

Sales per Business

Sales per region

Sector Other Pharmaceuticals

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Group companies

Sector

Sales per Business

Sales per region

Sector Other Pharmaceuticals

Inactive Instrument

End-of-day quote Xetra Other stock markets
- ^EUR	-

06/06	Novo Nordisk braces for Ozempic rivals in China	RE
06/06	European equities gain on tech boost in run-up to ECB	RE

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:

- diabetes and obesity treatment products (92.6%);

- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.

Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).

DKK in Million	2022	Weight	2023	Weight	Delta
Diabetes and Obesity Care 92.6 %	156,412	88.4 %	215,098	92.6 %	+37.52%
Rare Disease 7.4 %	20,542	11.6 %	17,163	7.4 %	-16.45%

DKK in Million	2022	Weight	2023	Weight	Delta
United States 54.9 %	84,656	47.8 %	127,534	54.9 %	+50.65%
EMEA 21.9 %	44,236	25.0 %	50,867	21.9 %	+14.99%
Rest of the World 12.1 %	25,402	14.4 %	28,078	12.1 %	+10.53%
China 7.2 %	16,209	9.2 %	16,687	7.2 %	+2.95%
Canada 3.9 %	6,451	3.6 %	9,095	3.9 %	+40.99%

Managers	Title	Age	Since
Lars Fruergaard Jorgensen CEO	Chief Executive Officer	58	01/91/01
Karsten Munk Knudsen DFI	Director of Finance/CFO	53	01/99/01
Stephen Gough CTO	Chief Tech/Sci/R&D Officer	-	01/15/01
Marcus Schindler CTO	Chief Tech/Sci/R&D Officer	57	01/18/01
Maziar Mike Doustdar COO	Chief Operating Officer	54	01/92/01
Henrik Ehlers Wulff CTO	Chief Tech/Sci/R&D Officer	54	01/99/01
Daniel Bohsen IRC	Investor Relations Contact	-	01/20/01
Tania Sabroe HRO	Human Resources Officer	47	01/07/01
Irina Ivanischeva LAW	General Counsel	-	-
Sergey Manelis PRN	Corporate Officer/Principal	-	13/20/13

Members of the board	Title	Age	Since
Sylvie Grégoire BRD	Director/Board Member	62	19/15/19
Helge Lund CHM	Chairman	61	23/17/23
Martin MacKay BRD	Director/Board Member	68	01/18/01
Kasim Kutay BRD	Director/Board Member	59	23/17/23
Andreas Fibig BRD	Director/Board Member	62	01/18/01
Henrik Poulsen BRD	Director/Board Member	57	25/21/25
Christina Law BRD	Director/Board Member	57	01/22/01
Mette Bøjer Jensen BRD	Director/Board Member	49	22/18/22
Thomas Rantzau BRD	Director/Board Member	52	22/18/22
Elisabeth Christensen BRD	Director/Board Member	59	24/22/24

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	10	1,075,000,000	0	0	70.17 %
Stock B	1	3,390,128,000	3,133,044,416 ( 92.42 %)	51,700,000 ( 1.525 %)

Name	Equities	%	Valuation
Novo Holdings A/S (Investment Company) 5.610 %	190,183,000	5.610 %	24 609 M €
NOVO NORDISK A/S 1.444 %	48,963,707	1.444 %	6 336 M €
State Street Global Advisors Ltd. 0.1910 %	6,476,746	0.1910 %	838 M €
Sjunde AP-fonden 0.1307 %	4,431,220	0.1307 %	573 M €
Eleva Capital LLP 0.1278 %	4,331,421	0.1278 %	560 M €
MFS International Singapore Pte Ltd. 0.1179 %	3,997,109	0.1179 %	517 M €
Amundi Asset Management SA (Investment Management) 0.1136 %	3,850,825	0.1136 %	498 M €
FMR Investment Management (UK) Ltd. 0.1102 %	3,735,699	0.1102 %	483 M €
Eurizon Capital SGR SpA 0.1086 %	3,680,515	0.1086 %	476 M €
Danske Bank A/S (Investment Management) 0.1079 %	3,656,541	0.1079 %	473 M €

Name	Equities	%	Valuation
Novo Holdings A/S (Investment Company) 100.00 %	1,074,872,000	100.00 %	139 B €
ANIMA Sgr SpA 0.0197 %	211,527	0.0197 %	27 M €
Fineco Asset Management DAC 0.009413 %	101,181	0.009413 %	13 M €
NS Partners SA 0.006408 %	68,876	0.006408 %	9 M €
Kieger AG 0.002940 %	31,596	0.002940 %	4 M €
Mercer Global Investments Europe Ltd. 0.002487 %	26,732	0.002487 %	3 M €
OLZ AG 0.001913 %	20,557	0.001913 %	3 M €
Union Bancaire Privée, UBP SA 0.001241 %	13,340	0.001241 %	2 M €
Swissinvest Institut für Angewandte Finanzmarktanalysen GmbH 0.000698 %	7,500	0.000698 %	970 489 €
Claresco Finance SA 0.000484 %	5,200	0.000484 %	672 872 €

Name	Equities	%	Valuation
Jennison Associates LLC 0.6219 %	21,084,614	0.6219 %	2 652 M €
Fidelity Management & Research Co. LLC 0.5193 %	17,604,322	0.5193 %	2 214 M €
Merrill Lynch International 0.4150 %	14,068,584	0.4150 %	1 770 M €
Fisher Asset Management LLC 0.4048 %	13,724,718	0.4048 %	1 726 M €
Eaton Vance Management 0.3543 %	12,011,853	0.3543 %	1 511 M €
Fayez Sarofim & Co. 0.3485 %	11,815,837	0.3485 %	1 486 M €
Renaissance Technologies LLC 0.3182 %	10,786,074	0.3182 %	1 357 M €
Royal Trust Corp. of Canada 0.2860 %	9,695,203	0.2860 %	1 220 M €
Loomis, Sayles & Co. LP 0.2611 %	8,852,532	0.2611 %	1 114 M €
Folketrygdfondet 0.2583 %	8,756,034	0.2583 %	1 101 M €

Name	Equities	%	Valuation
NOVO NORDISK A/S 1.44%	48,963,707	1.44%	6,335,831,220 $
NNIT A/S 17.50%	4,375,000	17.50%	67,111,319 $
INNATE PHARMA 12.14%	9,817,546	12.14%	23,146,828 $

Novo Nordisk A/S

Novo Allé 1

2880, Bagsværd

+45 44 44 88 88

http://www.novonordisk.com

Name	Category and Sector
Novo Nordisk India Pvt Ltd. Novo Nordisk India Pvt Ltd. Medical/Nursing ServicesHealth Services Part of Novo Nordisk A/S, Novo Nordisk India Pvt Ltd. is a leading healthcare company founded in 1923 and headquartered in Denmark. The company is based in Bengaluru, India. Novo Nordisk's purpose is to drive change to defeat diabetes and other serious chronic diseases.	Medical/Nursing Services
Velfærdsfonden for Novo Nordisk A/S	Investment Trusts/Mutual Funds
NNE A/S NNE A/S Engineering & ConstructionIndustrial Services Part of Novo Nordisk A/S, NNE A/S is a Danish company that supplies systems, consultancy and engineering services. The company is based in Soborg, Denmark.	Engineering & Construction
World Diabetes Foundation	Investment Trusts/Mutual Funds
Novo Nordisk Health Care AG Novo Nordisk Health Care AG Pharmaceuticals: MajorHealth Technology Novo Nordisk Health Care AG engages in the production and distribution of chemical and pharmaceutical products as well as articles for diagnostic and therapeutic applications. It also specializes in the research in and development of products, therapeutic methods, and display techniques primarily used in the chemical, pharmaceutical, and diagnostic fields. The company was founded on August 10, 2000 and is headquartered in Zurich, Switzerland.	Pharmaceuticals: Major
Novo Nordisk Finance (Netherlands) BV	Finance/Rental/Leasing
Novo Nordisk Region Europe A/S Novo Nordisk Region Europe A/S Financial ConglomeratesFinance Novo Nordisk Region Europe A/S holds ownership interests in other companies to undertake investment and financing activities. It offers service on an operational basis, including the placement of capital in companies and real estate. The company was founded September 14, 2001 and is headquartered in Bagsvaerd, Denmark.	Financial Conglomerates

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+45.82%	765B
JOHNSON & JOHNSON	-6.16%	354B
MERCK & CO., INC.	+19.86%	331B
ABBVIE INC.	+9.32%	299B
ASTRAZENECA PLC	+18.45%	248B
NOVARTIS AG	+11.88%	216B
ROCHE HOLDING AG	-0.78%	219B
AMGEN INC.	+5.90%	164B
PFIZER, INC.	-0.73%	162B

Other Pharmaceuticals

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Other Pharmaceuticals